AMLX

#2013
Amylyx Pharmaceuticals, Inc. Common Stock
16.92 USD
+2.73%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
16.92
16.92
Rango anual
3.79
17.49
Cambio diario
+2.73%
Variación mensual
+19.24%
Variación en los últimos 6 meses
+15.89%
Cambio anual
+332.74%
Cierres anteriores
16.47
Abrir
16.92
Bid
Ask
Mínimo
16.92
High
16.92
Volumen
87
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 1.87 B
  • Employee 136
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-7.9
Relación precio/flujo de caja
—

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Noticias